Teva API (TAPI)(TEVA)
HQ IL30% share
World's largest supplier of azithromycin API for regulated markets. TAPI is Teva's dedicated API business supplying both Teva's own generics and third-party manufacturers.
pharmaceutical · input
Azithromycin API
Active pharmaceutical ingredient for azithromycin (Z-Pack), a macrolide antibiotic. Semi-synthetic derivative of erythromycin A.
4
Source countries
3
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on azithromycin api somewhere upstream in their supply chain.
Who makes it
Supplier companies
3 companies produce azithromycin api.
Aurobindo Pharma Limited(AUROPHARMA.NS)
HQ IN15% share
Indian generic pharmaceutical company (NSE: AUROPHARMA; HQ Hyderabad, Telangana; ~$3.8B revenue); one of the world's largest generic API and finished dose manufacturers. Aurobindo holds INCB quota approvals for buprenorphine API manufacture in India and exports to regulated markets (US, EU). Aurobindo's controlled substance API operations leverage India's generic pharmaceutical industrial base to serve the post-patent-cliff buprenorphine/naloxone generic market. The company's API and formulation business spans more than 150 drug categories; buprenorphine is produced within its active pharmaceutical ingredients division alongside other Schedule II controlled substances (methadone, tramadol, fentanyl intermediates). Indian buprenorphine API production for export is constrained by INCB country-level quota allocations that limit the aggregate quantity India is authorized to manufacture annually. Aurobindo also produces buprenorphine/naloxone finished dose sublingual films and tablets at its US FDA-approved facilities, sourcing API from its own manufacturing or from other qualified suppliers.
Sun Pharmaceutical Industries Ltd.
HQ IN8% share
Indian pharmaceutical company (NSE: SUNPHARMA, HQ Mumbai; ~₹600B revenue); world's fourth-largest specialty generic pharmaceutical company and India's largest pharma company by market cap. Sun Pharma manufactures salbutamol sulfate API and finished albuterol inhalers (pMDI and nebulizer solution) at multiple Indian manufacturing sites, supplying US and global generic markets through its Taro Pharmaceutical US subsidiary. Sun Pharma was founded in 1983 by Dilip Shanghvi, who started with just five pharmaceutical products and a single employee; today Sun Pharma employs 36,000 people and operates 43 manufacturing sites globally. Sun Pharma's founder Dilip Shanghvi is now one of India's wealthiest individuals — his journey from a $1M startup to a $30B market cap company in 40 years is one of the defining business stories of India's pharmaceutical sector rise.